Study to Evaluate the Safety and Tolerability of KRX-0502 (Ferric Citrate) in Children With Iron Deficiency Anemia Associated With Non-Dialysis Dependent Chronic Kidney Disease

Ki vehet részt

• Age 6 years to <18 years at Screening
• Body Weight ≥12 kilograms (kg) at Screening
• Chronic kidney disease (CKD) stage 3 to 5, not on dialysis, with estimated glomerular filtration rate (eGFR) <60 milliliters per minute (mL/min)/1.73 meters squared (m\^2) utilizing the "Bedside Schwartz" equation
• Hemoglobin (Hgb) ≥8.5 and ≤11.5 grams per deciliter (g/dL) at Screening
• Transferrin saturation (TSAT) ≤25% at Screening
• Ferritin ≤200 nanograms per milliliter (ng/mL) at Screening

Ki nem vehet részt

• Intravenous iron therapy or blood transfusion within 4 weeks before the Screening visit
• Participants with a functioning organ transplant
• Receipt of any investigational drug within 4 weeks before Screening
• Active significant gastrointestinal (GI) disorder, including overt gastrointestinal (GI) bleeding or active inflammatory bowel disease
• Serum phosphorus level at Screening:; 6 to <13 years: ≤4.0 milligrams per deciliter (mg/dL); 13 to <18 years: ≤2.7 mg/dL
• Liver transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) ˃3× the upper limit of normal at Screening
• Unable to swallow pills
• Anemia due to causes other than iron deficiency anemia (IDA) of CKD
• Phosphate binder use during the Screening period